Key Insights

Highlights

Success Rate

94% trial completion (above average)

Published Results

60 trials with published results (24%)

Research Maturity

158 completed trials (64% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

4.1%

10 terminated out of 245 trials

Success Rate

94.0%

+7.5% vs benchmark

Late-Stage Pipeline

21%

52 trials in Phase 3/4

Results Transparency

38%

60 of 158 completed with results

Key Signals

60 with results94% success

Data Visualizations

Phase Distribution

198Total
Not Applicable (43)
Early P 1 (4)
P 1 (46)
P 2 (53)
P 3 (31)
P 4 (21)

Trial Status

Completed158
Unknown33
Recruiting21
Terminated10
Active Not Recruiting10
Not Yet Recruiting6

Trial Success Rate

94.0%

Benchmark: 86.5%

Based on 158 completed trials

Clinical Trials (245)

Showing 20 of 20 trials
NCT07535034Phase 2Not Yet RecruitingPrimary

A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants

NCT07367971Phase 1Recruiting

Drug-Drug Interaction Study of ABP-671 in Gout Patients

NCT05815901Phase 3Active Not RecruitingPrimary

A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients

NCT06229145Phase 4CompletedPrimary

A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

NCT05507723Not ApplicableRecruitingPrimary

Tight Control of Gouty Arthritis Compared to Usual Care

NCT07504146Recruiting

The Orienting Study

NCT07414394Phase 3RecruitingPrimary

Tigulixostat (IBI128) vs Febuxostat in Gout

NCT07490522Not ApplicableNot Yet RecruitingPrimary

The Remote Monitoring of Gout Feasibility Study in Primary Care

NCT07089875Phase 3RecruitingPrimary

A Study of Dotinurad Versus Allopurinol in Participants With Gout

NCT05658575Phase 2Recruiting

Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

NCT05289544Not ApplicableCompleted

Phone-Based Based Walk With Ease Program for Adults With Arthritis

NCT07116746Phase 2RecruitingPrimary

Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients

NCT04746989CompletedPrimary

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol

NCT07280156Phase 2RecruitingPrimary

A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)

NCT06669000RecruitingPrimary

Time Required to Dissolve Urate Deposits

NCT06887452Not ApplicableNot Yet RecruitingPrimary

Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients With Gout

NCT04733079Not ApplicableActive Not RecruitingPrimary

Treat-to-target by Email During Urate-lowering Therapy in Gout

NCT04844814Phase 2SuspendedPrimary

Anakinra vs Prednisone to Treat Gout Flare in Patients With Chronic Kidney Disease Stage 4/5 or Renal Transplantation

NCT05109936Phase 3RecruitingPrimary

Immediate Prescription of a Hypouricemic Treatment, Febuxostat, Compared to Its Delayed Administration

NCT07346079Phase 4Recruiting

Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares

Scroll to load more

Research Network

Activity Timeline